Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL
Authors:
- Kallesh D. JayappaKJKallesh D. Jayappa
- Briana WilsonBWBriana Wilson
- B. Dharmaveer ShettyBSB. Dharmaveer Shetty
- Konrad J. CiosKCKonrad J. Cios
- Krista M. IsaacKIKrista M. Isaac
- Shekhar SahaSSShekhar Saha
- Timothy P. BenderTBTimothy P. Bender
- Michael E. WilliamsMWMichael E. Williams
- Craig A. PortellCPCraig A. Portell
Open Access
- 13 September 2021
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (17) , 3497-3510
Abstract
The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts poor treatment outcomes. Consequently, additional proapoptotic drugs, such as inhibitors of Mcl-1 and Bcl-xL, are in development. By profiling antiapoptotic proteins using flow cytometry, we find that leukemic B cells that recently emigrated from the lymph node (CD69+/CXCR4Low) in vivo are enriched for cell clusters simultaneously overexpressing multiple antiapoptotic proteins (Mcl-1High/Bcl-xLHigh/Bcl-2High) in both treated and treatment-naive CLL patients. These cells exhibited antiapoptotic resistance to multiple BH-domain antagonists, including inhibitors of Bcl-2, Mcl-1, and Bcl-xL, when tested as single agents in a flow cytometry–based functional assay. Antiapoptotic multidrug resistance declines ex vivo, consistent with resistance being generated in vivo by extrinsic microenvironmental interactions. Surviving “persister” cells in patients undergoing venetoclax treatment are enriched for CLL cells displaying the functional and molecular properties of microenvironmentally induced multidrug resistance. Overcoming this resistance required simultaneous inhibition of multiple antiapoptotic proteins, with potential for unwanted toxicities. Using a drug screen performed using patient peripheral blood mononuclear cells cultured in an ex vivo microenvironment model, we identify novel venetoclax drug combinations that induce selective cytotoxicity in multidrug-resistant CLL cells. Thus, we demonstrate that antiapoptotic multidrug-resistant CLL cells exist in patients de novo and show that these cells persist during proapoptotic treatment, such as venetoclax. We validate clinically actionable approaches to selectively deplete this reservoir in patients.Keywords
This publication has 90 references indexed in Scilit:
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisionsCancer Letters, 2013
- BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial poreTrends in Biochemical Sciences, 2011
- CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling studyHaematologica, 2011
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737Blood, 2011
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling PathwayMolecular Cancer Therapeutics, 2011
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabBlood, 2009
- Expression of the Chemokine Receptors CXCR4 and CCR7 and Disease Progression in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMayo Clinic Proceedings, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002